Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer

Breast Cancer Clinical Trial

— BSMART  

Official title:

Breast Cancer Staging MAgnetic Resonance for Treatment (B-SMART)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00948285
• Other study ID #: A09-3519
• Status: Terminated
• Phase: N/A
• Start date: July 2009
• Est. completion date: December 2018

Study information

• Verified date: November 2019
• Source: Texas Tech University Health Sciences Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the use of magnetic resonance imaging (MRI) for breast cancer translates into better surgical outcomes. MRIs may help ensure that as little healthy tissue is removed as is possible and may help prevent the need for additional surgical procedures.

Description:

We propose that the role of preoperative staging-MRI in breast cancer be studied by following the occurrence of negative margins at first surgery and the volume of resection in a randomized prospective study. The need for re-excision is an objective marker of satisfactory local surgery and is available as soon as the final pathology report is back. We propose that the closest margin and the rate of re-excision be used as the primary outcome measures to evaluate the contribution of MRI. In addition, since cosmetic preservation is one of the goals of breast conservation, we propose that cosmetic outcome be used as the secondary outcome measure. The visual analogue scale for cosmetic outcome varies between observers and with time; however, the volume of tissue that is excised is an objective surrogate of cosmetic outcome.15 Since the excised volume is dictated by the tumor volume, the only variable under the surgeon's control is the volume of benign tissue excised in order to obtain negative margins. Hence, in this study, we propose to use a volume index of excised margins as an outcome measure for cosmesis. The index value will be calculated for each subject by adding the two measurements of benign margin for each of the three dimensions measured and multiplying them to produce a volume index for each subject.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 194
• Est. completion date: December 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Newly diagnosed breast cancer patients

• Breast cancer patients identified as conservation candidates by their surgeons

Exclusion Criteria:

• Patients with a history of prior breast cancer treatment (recurrence)

• Patients with breast cancer diagnosis during pregnancy (women who could bear children must have a negative pregnancy test before beginning this study)

• Patients with documented sensitivity to gadolinium (contrast agent used during MRI)

• Patients who weigh more than 350 pounds (weight limit on MRI machine)

• Patients who receive neoadjuvant chemotherapy

• Patients with renal insufficiency (serum Cr > 1.5) due to the danger of nephrogenic systemic sclerosis with the administration of Gadolinium

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• MRI
magnetic resonance imaging (MRI)

Locations

Country	Name	City	State
United States	Texas Tech University Health Sciences Center School of Medicine	Amarillo	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Texas Tech University Health Sciences Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A difference of 10% in the margin revision rate in women undergoing breast conservation for cancer.		3 years